Literature DB >> 7601402

Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase.

C Qian1, R Bilbao, O Bruña, J Prieto.   

Abstract

We have analyzed the ability of a recombinant replication-defective adenovirus to transfer the thymidine kinase gene of herpes simplex virus (HSV-tk) into hepatocellular carcinoma (HCC) cells to confer sensitivity to ganciclovir. Three HCC cell lines (Hep3B, PLC/PRF/5, and HepG2) were efficiently infected in vitro by a recombinant adenovirus carrying lacZ reporter gene (AdCMVlacZ). Expression of HSV-tk in HCC cells infected with a recombinant adenovirus carrying HSV-tk gene (AdCMVtk) induced sensitivity to ganciclovir in a dose-dependent manner. A bystander killing effect was observed when 90% of uninfected tumor cells were mixed with only 10% of AdCMVtk-infected cells. These data show that recombinant adenoviruses are efficient vectors for transduction of drug-sensitizing genes to HCC cells in vitro. We suggest that a gene therapy approach to hepatocellular carcinoma can be established using adenoviral transfer of HSV-tk to tumor cells and subsequent administration of ganciclovir.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7601402

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Liver damage using suicide genes. A model for oval cell activation.

Authors:  M Bustos; B Sangro; P Alzuguren; A G Gil; J Ruiz; N Beraza; C Qian; A Garcia-Pardo; J Prieto
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  An in vitro nucleoside analog screening method for cancer gene therapy.

Authors:  A Evrard; L Vian; C Aubert; J P Cano
Journal:  Cell Biol Toxicol       Date:  1996-12       Impact factor: 6.691

4.  Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems.

Authors:  Luciana Meli; Eric T Jordan; Douglas S Clark; Robert J Linhardt; Jonathan S Dordick
Journal:  Biomaterials       Date:  2012-09-19       Impact factor: 12.479

Review 5.  Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.

Authors:  Yi-Gang Wang; Pan-Pan Huang; Rong Zhang; Bu-Yun Ma; Xiu-Mei Zhou; Yan-Fang Sun
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  Gene therapy of HSV-TK transferred by the EBV based expression vector on experimental hepatocellular carcinoma.

Authors:  Q Ding; Z Wu; X Chen; A H Musa; J Hu; Y Zhan
Journal:  J Tongji Med Univ       Date:  2001

7.  Specific targeting of pancreatic islet cells in vivo by insulin-promoter-driven adenoviral conjugated reporter genes.

Authors:  Xiaoping Wang; Elizabeth Olmsted-Davis; Alan Davis; Shihe Liu; Zhijun Li; Jie Yang; F Charles Brunicardi
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

8.  Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.

Authors:  Hua-Jung Li; Maaike Everts; Masato Yamamoto; David T Curiel; Harvey R Herschman
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

9.  A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice.

Authors:  Juan E Puche; Youngmin A Lee; Jingjing Jiao; Costica Aloman; Maria I Fiel; Ursula Muñoz; Thomas Kraus; Tingfang Lee; Hal F Yee; Scott L Friedman
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

10.  Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells.

Authors:  Satoshi Okabe; Takehiro Arai; Hironori Yamashita; Kenichi Sugihara
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.